Suzanne M Boyle1, Kallie Fehr2, Catylin Deering3, Abbas Raza2, Meera N Harhay2,4,5, Gregory Malat6, Karthik Ranganna2,5, Dong Heun Lee7. 1. Division Nephrology, Hypertension and Kidney Transplantation, Department of Medicine, Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania. 2. Department of Medicine, Drexel University College of Medicine, Philadelphia, Pennsylvania. 3. Division of Infectious Disease, Department of Medicine, University of Toledo College of Medicine and Life Sciences, Toledo, Ohio. 4. Department of Epidemiology and Biostatistics, Dornsife School of Public Health, Drexel University, Philadelphia, Pennsylvania. 5. Tower Health System, Tower Health Transplant Institute, West Reading, Pennsylvania. 6. Department of Medicine, Renal, Electrolyte and Hypertension Division, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. 7. Division of Infectious Disease and HIV Medicine, Department of Medicine, Drexel University College of Medicine, Philadelphia, Pennsylvania.
Abstract
BACKGROUND: HIV-positive kidney transplant (KT) recipients have similar outcomes to HIV-negative recipients. However, HIV-positive patients with advanced kidney disease might face additional barriers to initiating the KT evaluation process. We sought to characterize comorbidities, viral control and management, viral resistance, and KT evaluation appointment rates in a cohort of KT evaluation-eligible HIV-positive patients. METHODS: We included patients seen between January 1, 2008, and December 31, 2015, at a primary care HIV clinic who met KT evaluation eligibility by an estimated glomerular filtration rate ≤20 mL/min/1.73 meters2 or dialysis dependence. The primary outcome was a documented appointment for KT evaluation. RESULTS: Of 3735 patients evaluated at the HIV primary clinic during the study period, 42 (1.6%) were KT evaluation-eligible patients. The median age was 47 years, 77% were male, and 95%, black. Median CD4 count was 328 cells/mm3 (IQR 175-461). Among the 63% percent with antiretroviral therapy (ART) prescription, 40% had viral loads >200 copies. Among patients with HIV resistance profiles (50%, n = 21), 52% had resistance to at least one class of ART. A majority (60%, n = 25) were scheduled for KT evaluation appointment, but of those, only 8% (n = 2) had evidence of appointments before dialysis dependence. Those without appointments had more schizophrenia (29% vs 4%, P = .02), resistance (78% vs 33%, P = .04), ART prescription (76% vs 48%, P = .04), and more kidney disease of unknown etiology (53% vs 8%, P = .02). CONCLUSION: Kidney transplant evaluation-eligible HIV-positive patients had a high rate of evaluation appointments, but a low rate of preemptive evaluation appointments. Schizophrenia and viral resistance disproportionally affected patients without evaluation appointments. These data precede the recommendation for universal ART for all HIV+ patients, regardless of CD4 count and viral load, and must be interpreted in the context of this limitation.
BACKGROUND: HIV-positive kidney transplant (KT) recipients have similar outcomes to HIV-negative recipients. However, HIV-positive patients with advanced kidney disease might face additional barriers to initiating the KT evaluation process. We sought to characterize comorbidities, viral control and management, viral resistance, and KT evaluation appointment rates in a cohort of KT evaluation-eligible HIV-positive patients. METHODS: We included patients seen between January 1, 2008, and December 31, 2015, at a primary care HIV clinic who met KT evaluation eligibility by an estimated glomerular filtration rate ≤20 mL/min/1.73 meters2 or dialysis dependence. The primary outcome was a documented appointment for KT evaluation. RESULTS: Of 3735 patients evaluated at the HIV primary clinic during the study period, 42 (1.6%) were KT evaluation-eligible patients. The median age was 47 years, 77% were male, and 95%, black. Median CD4 count was 328 cells/mm3 (IQR 175-461). Among the 63% percent with antiretroviral therapy (ART) prescription, 40% had viral loads >200 copies. Among patients with HIV resistance profiles (50%, n = 21), 52% had resistance to at least one class of ART. A majority (60%, n = 25) were scheduled for KT evaluation appointment, but of those, only 8% (n = 2) had evidence of appointments before dialysis dependence. Those without appointments had more schizophrenia (29% vs 4%, P = .02), resistance (78% vs 33%, P = .04), ART prescription (76% vs 48%, P = .04), and more kidney disease of unknown etiology (53% vs 8%, P = .02). CONCLUSION: Kidney transplant evaluation-eligible HIV-positive patients had a high rate of evaluation appointments, but a low rate of preemptive evaluation appointments. Schizophrenia and viral resistance disproportionally affected patients without evaluation appointments. These data precede the recommendation for universal ART for all HIV+ patients, regardless of CD4 count and viral load, and must be interpreted in the context of this limitation.
Authors: Samir K Gupta; Joseph A Eustace; Jonathan A Winston; Ivy I Boydstun; Tejinder S Ahuja; Rudolph A Rodriguez; Karen T Tashima; Michelle Roland; Nora Franceschini; Frank J Palella; Jeffrey L Lennox; Paul E Klotman; Sharon A Nachman; Stephen D Hall; Lynda A Szczech Journal: Clin Infect Dis Date: 2005-04-22 Impact factor: 9.079
Authors: Gregory E Malat; Suzanne M Boyle; Rahul M Jindal; Stephen Guy; Gary Xiao; Meera N Harhay; Dong H Lee; Karthik M Ranganna; Mysore S Anil Kumar; Alden M Doyle Journal: Am J Kidney Dis Date: 2018-04-25 Impact factor: 8.860
Authors: Jordana B Cohen; Jayme E Locke; Brittany Shelton; Rhiannon D Reed; Margaux Mustian; Paul MacLennan; Kimberly A Forde; Peter P Reese; Deirdre Sawinski Journal: Clin Transplant Date: 2019-01-12 Impact factor: 2.863
Authors: D Sawinski; B A Shelton; S Mehta; R D Reed; P A MacLennan; S Gustafson; D L Segev; J E Locke Journal: Am J Transplant Date: 2017-08-24 Impact factor: 8.086
Authors: Peter G Stock; Burc Barin; Barbara Murphy; Douglas Hanto; Jorge M Diego; Jimmy Light; Charles Davis; Emily Blumberg; David Simon; Aruna Subramanian; J Michael Millis; G Marshall Lyon; Kenneth Brayman; Doug Slakey; Ron Shapiro; Joseph Melancon; Jeffrey M Jacobson; Valentina Stosor; Jean L Olson; Donald M Stablein; Michelle E Roland Journal: N Engl J Med Date: 2010-11-18 Impact factor: 91.245
Authors: D Sawinski; C M Wyatt; L Casagrande; P Myoung; I Bijan; E Akalin; B Schröppel; G DeBoccardo; V Sehgal; R Dinavahi; S Lerner; S Ames; J Bromberg; S Huprikar; M Keller; B Murphy Journal: Am J Transplant Date: 2009-05-13 Impact factor: 8.086
Authors: Gregory M Lucas; Bryan Lau; Mohamed G Atta; Derek M Fine; Jeanne Keruly; Richard D Moore Journal: J Infect Dis Date: 2008-06-01 Impact factor: 5.226